
Granata Bio, a biopharma company targeting the $3.6B global infertility medication market, has secured $15 million in Series A+ funding. The round was supported exclusively by existing investors, including women’s health leaders Gedeon Richter and CooperSurgical, along with Amboy Street Ventures and other strategic investors, bringing the company’s total funding to over $30 million.
The Boston-based company plans to use the funding to advance its existing pipeline and explore new innovative assets in reproductive health. Founded in 2018, Granata’s pipeline includes collaborations across multiple IVF product classes.
“We are grateful for the continued confidence and commitment shown by our existing investors, especially our strategic partners who are leaders in women’s health, Gedeon Richter and CooperSurgical. Granata Bio is committed to improving access for fertility patients by identifying and developing new therapeutic solutions. With this new funding, we are well-positioned to accelerate the development of our current and future pipeline,” said Evan Sussman, CEO of Granata Bio.
The round demonstrates continued support from major players in women’s health, with Gedeon Richter bringing expertise in steroid chemistry and women’s healthcare, while CooperSurgical contributes experience in assisted reproductive technology and genomic solutions.